首页 > 最新文献

Korean journal of ophthalmology : KJO最新文献

英文 中文
Clinical Features of Leber Hereditary Optic Neuropathy Carrying a Rare m.13051G>A Mitochondrial Mutation: A Case Report. 携带罕见m.13051G> a mtDNA突变的Leber遗传性视神经病变的临床特征
Pub Date : 2025-12-01 Epub Date: 2025-09-23 DOI: 10.3341/kjo.2025.0086
Hyuna Kim, Hee Kyung Yang, Moon-Woo Seong, Jeong-Min Hwang
{"title":"Clinical Features of Leber Hereditary Optic Neuropathy Carrying a Rare m.13051G>A Mitochondrial Mutation: A Case Report.","authors":"Hyuna Kim, Hee Kyung Yang, Moon-Woo Seong, Jeong-Min Hwang","doi":"10.3341/kjo.2025.0086","DOIUrl":"10.3341/kjo.2025.0086","url":null,"abstract":"","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"586-588"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Overview of the Therapeutic Applications of Tinted Lenses Spectacles. 有色镜片眼镜的治疗应用综述。
Pub Date : 2025-12-01 Epub Date: 2025-09-16 DOI: 10.3341/kjo.2025.0077
Masoumeh Ahadi, Afsaneh Ebrahimi, Ali Abbasi, Akmal Karimovich Matkarimov

Although tinted glasses are part of the fashion and beauty world, these glasses have various therapeutic applications in normal people or people with eye and neurological problems in some cases have been ignored. Tinted spectacles produce their effects by reducing visible light transmission and filtering by removing a certain part of the spectrum and can reduce discomfort and annoyance and improve the quality of life. The therapeutic effects of these glasses are related to controlling photophobia, preventing glare and increasing contrast. These glasses are used in normal people as sunglasses, to improve sports activities, comfortable driving at night and to increase sleep quality. Colored glasses have also been widely used in people with low vision related to congenital and acquired retinal diseases and neurological diseases such as migraine, acquired brain injury, and photosensitive epilepsy. So far, numerous studies have been conducted on the beneficial and therapeutic effects of colored glasses, which sometimes report contradictory effects. In this article, we explore the therapeutic uses of colored glasses in more detail.

虽然有色眼镜是时尚和美丽世界的一部分,但它们在正常人或有眼部和神经问题的人身上有各种治疗用途,而这些在某些情况下被忽视了。本文综述了有色晶状体的治疗应用。
{"title":"An Overview of the Therapeutic Applications of Tinted Lenses Spectacles.","authors":"Masoumeh Ahadi, Afsaneh Ebrahimi, Ali Abbasi, Akmal Karimovich Matkarimov","doi":"10.3341/kjo.2025.0077","DOIUrl":"10.3341/kjo.2025.0077","url":null,"abstract":"<p><p>Although tinted glasses are part of the fashion and beauty world, these glasses have various therapeutic applications in normal people or people with eye and neurological problems in some cases have been ignored. Tinted spectacles produce their effects by reducing visible light transmission and filtering by removing a certain part of the spectrum and can reduce discomfort and annoyance and improve the quality of life. The therapeutic effects of these glasses are related to controlling photophobia, preventing glare and increasing contrast. These glasses are used in normal people as sunglasses, to improve sports activities, comfortable driving at night and to increase sleep quality. Colored glasses have also been widely used in people with low vision related to congenital and acquired retinal diseases and neurological diseases such as migraine, acquired brain injury, and photosensitive epilepsy. So far, numerous studies have been conducted on the beneficial and therapeutic effects of colored glasses, which sometimes report contradictory effects. In this article, we explore the therapeutic uses of colored glasses in more detail.</p>","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"550-565"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145071587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative Full-Thickness Macular Hole Formation after Vitrectomy for the Removal of Epiretinal Membrane. 玻璃体切除视网膜前膜后全层黄斑孔的形成。
Pub Date : 2025-12-01 Epub Date: 2025-09-02 DOI: 10.3341/kjo.2025.0107
Hyun Ji Jung, Hyun Jin Kim, Soo Chang Cho

Purpose: To evaluate the incidence, clinical features, risk factors, and outcomes of full-thickness macular hole (MH) formation after pars plana vitrectomy (PPV) for the removal of epiretinal membrane (ERM).

Methods: This retrospective study reviewed the medical charts of the 309 eyes of 306 patients with PPV for ERM removal from 2012 to 2024 using clinical data warehouse search. Patients were categorized into two groups: one group with development of MH and the other without MH development after ERM surgery. Baseline demographics and clinical parameters were compared between the two groups. Risk factors for MH formation were analyzed using univariate and multivariate logistic regression. Surgical outcomes of the cases with MH formation were also analyzed.

Results: A total of 141 eyes were included. Five cases (3.5%) developed MH after PPV for ERM removal. In all five cases (100%), ERM was observed at MH detection. In four of the five patients (80%), cystoid macular edema (CME) was present at MH detection. ERM with lamellar hole was significantly associated factors for MH formation (odds ratio [OR], 13.11; p = 0.018). Preoperative central macular thickness (CMT) showed a marginal association (OR, 0.98; p = 0.075). Among the four patients who underwent surgery, macular hole was successfully closed in three cases. There was no significant difference in best-corrected visual acuity before and after MH surgery.

Conclusions: ERM with lamellar hole was a significant factor for MH formation, while thin preoperative CMT showed a marginal association. At the time of MH detection, ERM and CME were observed in most cases, suggesting that tangential traction caused by postoperative ERM or, postoperative CME may represent possible etiologies for MH formation. In patients with ERM with lamellar hole or thin CMT, the possibility of MH formation after ERM surgery should be taken into account and careful monitoring is needed.

目的:探讨玻璃体切除(PPV)术后全层黄斑裂孔(FTMH)形成的发生率、临床特征、危险因素及预后。方法:采用临床数据仓库检索的方法,对2012年至2024年306例PPV患者的309眼ERM切除病历进行回顾性研究。患者分为两组;ERM术后出现黄斑裂孔(MH)组(“MH”组)和未出现MH组(“no MH”组)。比较两组患者的基线人口统计学和临床参数。采用单因素和多因素logistic回归分析MH形成的危险因素。并对MH形成病例的手术结果进行分析。结果:共纳入141只眼。5例患者在PPV切除ERM后发生MH(发生率3.5%)。在所有5例(100%)中,在MH检测中观察到ERM。5例患者中有4例(80%)在MH检测时出现CME。带板层孔的ERM是MH形成的显著相关因素(OR=13.11, P=0.018)。术前黄斑中央厚度(CMT)呈边缘相关性(OR=0.98, P=0.075)。4例手术患者中,有3例黄斑孔闭合成功。MH手术前后BCVA无显著差异。结论:ERM与LH是MH形成的重要因素,而术前薄CMT显示出边际关联。在MH检测时,大多数病例观察到ERM和CME,提示术后ERM或术后CME引起的切向牵引可能是MH形成的可能原因。对于伴有LH或薄CMT的ERM患者,应考虑ERM术后MH形成的可能性,并需要仔细监测。
{"title":"Postoperative Full-Thickness Macular Hole Formation after Vitrectomy for the Removal of Epiretinal Membrane.","authors":"Hyun Ji Jung, Hyun Jin Kim, Soo Chang Cho","doi":"10.3341/kjo.2025.0107","DOIUrl":"10.3341/kjo.2025.0107","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the incidence, clinical features, risk factors, and outcomes of full-thickness macular hole (MH) formation after pars plana vitrectomy (PPV) for the removal of epiretinal membrane (ERM).</p><p><strong>Methods: </strong>This retrospective study reviewed the medical charts of the 309 eyes of 306 patients with PPV for ERM removal from 2012 to 2024 using clinical data warehouse search. Patients were categorized into two groups: one group with development of MH and the other without MH development after ERM surgery. Baseline demographics and clinical parameters were compared between the two groups. Risk factors for MH formation were analyzed using univariate and multivariate logistic regression. Surgical outcomes of the cases with MH formation were also analyzed.</p><p><strong>Results: </strong>A total of 141 eyes were included. Five cases (3.5%) developed MH after PPV for ERM removal. In all five cases (100%), ERM was observed at MH detection. In four of the five patients (80%), cystoid macular edema (CME) was present at MH detection. ERM with lamellar hole was significantly associated factors for MH formation (odds ratio [OR], 13.11; p = 0.018). Preoperative central macular thickness (CMT) showed a marginal association (OR, 0.98; p = 0.075). Among the four patients who underwent surgery, macular hole was successfully closed in three cases. There was no significant difference in best-corrected visual acuity before and after MH surgery.</p><p><strong>Conclusions: </strong>ERM with lamellar hole was a significant factor for MH formation, while thin preoperative CMT showed a marginal association. At the time of MH detection, ERM and CME were observed in most cases, suggesting that tangential traction caused by postoperative ERM or, postoperative CME may represent possible etiologies for MH formation. In patients with ERM with lamellar hole or thin CMT, the possibility of MH formation after ERM surgery should be taken into account and careful monitoring is needed.</p>","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"479-492"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Efficacy of Electrical Auricular Transcutaneous Stimulation for Dry Eye: A Sham-Controlled, Randomized Trial. 经皮耳电刺激治疗干眼症的临床疗效:一项假对照随机试验。
Pub Date : 2025-12-01 Epub Date: 2025-09-19 DOI: 10.3341/kjo.2025.0087
Yeon Ji Jo, Jae Hyun Kim, Jong Soo Lee

Purpose: This study aimed to evaluate the clinical efficacy of low-frequency ear transcutaneous stimulation (TS) for improving ocular symptoms and signs in patients with dry eye disease (DED). The primary outcome was the Ocular Surface Disease Index (OSDI) score difference between TS and sham groups, while secondary outcomes included tear breakup time (TBUT), Schirmer test (strip meniscometry tube, SMTube), and corneal staining (National Eye Institute [NEI] score).

Methods: Patients with a TBUT <5 seconds and tear volume by Schirmer test <5 mm, along with ocular symptoms, were randomized into a TS treatment group (n = 25) and a sham group (n = 24). The TS treatment device was applied bilaterally twice daily for 8 weeks, with each session lasting 30 minutes. The OSDI questionnaire score, corneal and conjunctival stain score (NEI score), TBUT, and tear secretion volume (SMTube) were analyzed at baseline and 4 and 8 weeks after treatment.

Results: The sham group showed no significant changes in any parameters at 4 and 8 weeks. The TS group demonstrated significant improvements in NEI score, TBUT, and SM tube values at both 4 and 8 weeks compared to the sham group (p = 0.002, p = 0.001, and p = 0.017, respectively, at 4 weeks; p = 0.001, p = 0.001, and p = 0.001, respectively, at 8 weeks). No significant difference in OSDI was found between groups at 4 weeks (p = 0.061), but at 8 weeks, the TS group showed a significantly greater improvement (p = 0.018).

Conclusions: The low-frequency ear TS device significantly improved DED symptoms and objective measures compared to the sham group. These findings support the potential of TS as a novel treatment option for DED.

背景:本研究旨在评价低频耳经皮刺激(TS)改善干眼病(DED)患者眼部症状和体征的临床疗效。主要转归是TS组和假手术组的眼表疾病指数(OSDI)评分差异,次要转归包括泪液破裂时间(TBUT)、Schirmer试验(SM管)和角膜染色(National Eye Institute [NEI]评分)。方法:泪膜破裂时间(TBUT) < 5 s, Schirmer试验泪液体积< 5 mm,伴有眼部症状的患者随机分为TS治疗组(n=25)和假手术组(n=24)。TS治疗装置双侧应用,每天2次,持续8周,每次持续30分钟。分别在基线及治疗后4、8周进行眼表疾病指数(OSDI)问卷评分、角膜及结膜染色评分(National Eye Institute [NEI])、TBUT、泪液分泌量(SM管)的分析。结果:假手术组4、8周各指标无明显变化。与假手术组相比,TS组在4周和8周时NEI评分、TBUT和SM管值均有显著改善(4周时p= 0.002、0.001、0.017;8周时p= 0.001、0.001和0.001)。4周时各组间OSDI差异无统计学意义(p= 0.061), 8周时TS组改善明显(p= 0.018)。结论:与假手术组相比,低频耳部TS装置明显改善了DED的症状和客观指标。这些发现支持TS作为DED新治疗选择的潜力。
{"title":"Clinical Efficacy of Electrical Auricular Transcutaneous Stimulation for Dry Eye: A Sham-Controlled, Randomized Trial.","authors":"Yeon Ji Jo, Jae Hyun Kim, Jong Soo Lee","doi":"10.3341/kjo.2025.0087","DOIUrl":"10.3341/kjo.2025.0087","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the clinical efficacy of low-frequency ear transcutaneous stimulation (TS) for improving ocular symptoms and signs in patients with dry eye disease (DED). The primary outcome was the Ocular Surface Disease Index (OSDI) score difference between TS and sham groups, while secondary outcomes included tear breakup time (TBUT), Schirmer test (strip meniscometry tube, SMTube), and corneal staining (National Eye Institute [NEI] score).</p><p><strong>Methods: </strong>Patients with a TBUT <5 seconds and tear volume by Schirmer test <5 mm, along with ocular symptoms, were randomized into a TS treatment group (n = 25) and a sham group (n = 24). The TS treatment device was applied bilaterally twice daily for 8 weeks, with each session lasting 30 minutes. The OSDI questionnaire score, corneal and conjunctival stain score (NEI score), TBUT, and tear secretion volume (SMTube) were analyzed at baseline and 4 and 8 weeks after treatment.</p><p><strong>Results: </strong>The sham group showed no significant changes in any parameters at 4 and 8 weeks. The TS group demonstrated significant improvements in NEI score, TBUT, and SM tube values at both 4 and 8 weeks compared to the sham group (p = 0.002, p = 0.001, and p = 0.017, respectively, at 4 weeks; p = 0.001, p = 0.001, and p = 0.001, respectively, at 8 weeks). No significant difference in OSDI was found between groups at 4 weeks (p = 0.061), but at 8 weeks, the TS group showed a significantly greater improvement (p = 0.018).</p><p><strong>Conclusions: </strong>The low-frequency ear TS device significantly improved DED symptoms and objective measures compared to the sham group. These findings support the potential of TS as a novel treatment option for DED.</p>","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"513-523"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bilateral Epstein-Barr Virus Keratitis Confirmed via Tear Polymerase Chain Reaction: A Case Report. 泪液聚合酶链反应确诊双侧eb病毒角膜炎1例
Pub Date : 2025-12-01 Epub Date: 2025-09-16 DOI: 10.3341/kjo.2025.0091
Min Ji Kang, Roo Min Jun, Kyung Eun Han
{"title":"Bilateral Epstein-Barr Virus Keratitis Confirmed via Tear Polymerase Chain Reaction: A Case Report.","authors":"Min Ji Kang, Roo Min Jun, Kyung Eun Han","doi":"10.3341/kjo.2025.0091","DOIUrl":"10.3341/kjo.2025.0091","url":null,"abstract":"","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"583-585"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145071556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer-Associated Retinopathy in a Patient with Small Cell Lung Cancer and Esophageal Cancer: A Case Report. 小细胞肺癌和食管癌患者的肿瘤相关视网膜病变1例报告。
Pub Date : 2025-12-01 Epub Date: 2025-10-16 DOI: 10.3341/kjo.2025.0124
Woosung Jeon, Hye Kyoung Hong, Min Seok Kim, Kwangsic Joo
{"title":"Cancer-Associated Retinopathy in a Patient with Small Cell Lung Cancer and Esophageal Cancer: A Case Report.","authors":"Woosung Jeon, Hye Kyoung Hong, Min Seok Kim, Kwangsic Joo","doi":"10.3341/kjo.2025.0124","DOIUrl":"10.3341/kjo.2025.0124","url":null,"abstract":"","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"591-593"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Birdshot Chorioretinopathy Successfully Treated with Adalimumab: A Case Report. 阿达木单抗成功治疗鸟射性脉络膜视网膜病变1例。
Pub Date : 2025-12-01 Epub Date: 2025-09-30 DOI: 10.3341/kjo.2024.0134
Young Kun Suh, Se Joon Woo
{"title":"Birdshot Chorioretinopathy Successfully Treated with Adalimumab: A Case Report.","authors":"Young Kun Suh, Se Joon Woo","doi":"10.3341/kjo.2024.0134","DOIUrl":"10.3341/kjo.2024.0134","url":null,"abstract":"","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"589-590"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraoperative and postoperative suprachoroidal hemorrhage in pediatric patients undergoing penetrating keratoplasty or Ahmed valve implantation. 穿透性角膜移植术或Ahmed瓣膜植入术患儿术中及术后脉络膜上出血。
Pub Date : 2025-12-01 Epub Date: 2025-09-30 DOI: 10.3341/kjo.2025.0079
Se Hee Min, Young Kook Kim, Joo Youn Oh

Purpose: This retrospective case series aims to characterize the ocular findings, clinical presentation, management, and outcomes of suprachoroidal hemorrhage (SCH) in pediatric patients undergoing penetrating keratoplasty (PK) or Ahmed glaucoma valve (AGV) implantation.

Methods: From 2012 to 2023, a total of 58 pediatric patients underwent PK, and 89 underwent AGV implantation at our institution. Among these, three perioperative SCH cases were identified. Medical records, anterior segment photographs, and ultrasonographic images of these patients were reviewed.

Results: All three patients had Peters anomaly, congenital glaucoma (CG), and aniridia in both eyes. In case 1 with Peters anomaly, CG, and partial aniridia, SCH developed intraoperatively in an aphakic eye during the third PK. In case 2 with Peters anomaly, CG, and total aniridia, SCH was observed 1 day after PK and lensectomy. In case 3 with Peters anomaly, CG, and partial aniridia, SCH occurred 2 days after AGV implantation in a pseudophakic eye with prior PK and cataract surgery. SCH resolved with conservative management in all cases. However, cases 1 and 2 ultimately lost light perception, while case 3 achieved a best-corrected visual acuity of 0.06.

Conclusions: The risk of intraoperative and delayed SCH should be considered in eyes with Peters anomaly, CG, and aniridia during intraocular surgeries that involve significant intraocular pressure fluctuations.

目的:本回顾性病例系列旨在描述行穿透性角膜移植术(PK)或Ahmed青光眼瓣膜(AGV)植入术的儿童患者的眼部表现、临床表现、处理和结果。方法:2012 - 2023年,我院共58例患儿行PK, 89例患儿行AGV植入。其中围手术期SCH病例3例。我们回顾了这些患者的医疗记录、前段照片和超声图像。结果:3例患者均有彼得斯异常、先天性青光眼、双眼无虹膜。病例1伴有彼得斯异常、CG和部分无虹膜,术中无晶状体眼在第三次PK时发生SCH。病例2伴有彼得斯异常、CG和完全无虹膜,在PK和晶状体切除术后一天观察到SCH。病例3伴有彼得斯异常、CG和部分无虹膜,在假晶状眼植入AGV后2天发生SCH,该假晶状眼之前进行过PK和白内障手术。所有病例均采用保守治疗。然而,病例1和2最终失去了光知觉,而病例3的最佳矫正视力为0.06。结论:对于有彼得斯异常、CG和无虹膜的眼,在眼压波动较大的眼内手术中,应考虑术中和延迟性SCH的风险。
{"title":"Intraoperative and postoperative suprachoroidal hemorrhage in pediatric patients undergoing penetrating keratoplasty or Ahmed valve implantation.","authors":"Se Hee Min, Young Kook Kim, Joo Youn Oh","doi":"10.3341/kjo.2025.0079","DOIUrl":"10.3341/kjo.2025.0079","url":null,"abstract":"<p><strong>Purpose: </strong>This retrospective case series aims to characterize the ocular findings, clinical presentation, management, and outcomes of suprachoroidal hemorrhage (SCH) in pediatric patients undergoing penetrating keratoplasty (PK) or Ahmed glaucoma valve (AGV) implantation.</p><p><strong>Methods: </strong>From 2012 to 2023, a total of 58 pediatric patients underwent PK, and 89 underwent AGV implantation at our institution. Among these, three perioperative SCH cases were identified. Medical records, anterior segment photographs, and ultrasonographic images of these patients were reviewed.</p><p><strong>Results: </strong>All three patients had Peters anomaly, congenital glaucoma (CG), and aniridia in both eyes. In case 1 with Peters anomaly, CG, and partial aniridia, SCH developed intraoperatively in an aphakic eye during the third PK. In case 2 with Peters anomaly, CG, and total aniridia, SCH was observed 1 day after PK and lensectomy. In case 3 with Peters anomaly, CG, and partial aniridia, SCH occurred 2 days after AGV implantation in a pseudophakic eye with prior PK and cataract surgery. SCH resolved with conservative management in all cases. However, cases 1 and 2 ultimately lost light perception, while case 3 achieved a best-corrected visual acuity of 0.06.</p><p><strong>Conclusions: </strong>The risk of intraoperative and delayed SCH should be considered in eyes with Peters anomaly, CG, and aniridia during intraocular surgeries that involve significant intraocular pressure fluctuations.</p>","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"524-531"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of Re-Switching Anti-Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration. 年龄相关性黄斑变性患者勃罗单抗相关炎症后再转换抗血管内皮生长因子的结果。
Pub Date : 2025-12-01 Epub Date: 2025-09-16 DOI: 10.3341/kjo.2025.0008
Young Kun Suh, Seok Hee Lee, Min Seok Kim

Purpose: To investigate the anatomical and functional outcomes in cases of re-switching to previous anti?vascular endothelial growth factor (anti-VEGF) agents due to intraocular inflammation (IOI) following a switch to brolucizumab in neovascular age-related macular degeneration.

Methods: This study included patients with neovascular age-related macular degeneration who switched to brolucizumab and discontinued brolucizumab treatment due to IOI, with a follow-up duration of at least 6 months before and after brolucizumab treatment period. Changes in best-corrected visual acuity, central macular thickness, central choroidal thickness, and retinal fluid on optical coherence tomography were evaluated.

Results: A total of 16 eyes from 16 patients were reviewed. Two patients (12.5%) achieved complete fluid resolution before brolucizumab treatment, which increased to 15 (93.8%) during brolucizumab therapy. However, after switching back to other anti-VEGF agents, the proportion of patients with dry macula decreased to 37.5%. There were no statistically significant changes in best-corrected visual acuity, central macular thickness, central choroidal thickness throughout the study period.

Conclusions: In cases where brolucizumab treatment was discontinued due to IOI and switched back to other anti-VEGF agents, the anatomical response was insufficient, indicating the need for alternative treatment options.

目的:研究在新生血管性年龄相关性黄斑变性(nAMD)患者中,由于眼内炎症(IOI)而切换到先前的抗血管内皮生长因子(VEGF)药物后,再切换到先前的抗血管内皮生长因子(VEGF)药物的解剖和功能结果。方法:本研究纳入了因IOI而切换到brolucizumab治疗并停止brolucizumab治疗的nAMD患者,在brolucizumab治疗期前后随访至少6个月。评价光学相干断层扫描最佳矫正视力(BCVA)、中央黄斑厚度(CMT)、中央脉络膜厚度(CCT)和视网膜液的变化。结果:16例患者共16只眼。12.5%的患者在布卢珠单抗治疗前达到完全液体溶解,在布卢珠单抗治疗期间增加到93.8%。然而,在切换回其他抗vegf药物后,干性黄斑患者的比例下降到37.5%。在整个研究期间,BCVA、CMT或CCT没有统计学上的显著变化。结论:在因IOI而停止brolucizumab治疗并切换回其他抗vegf药物的病例中,解剖反应不足,表明需要替代治疗方案。
{"title":"Outcomes of Re-Switching Anti-Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration.","authors":"Young Kun Suh, Seok Hee Lee, Min Seok Kim","doi":"10.3341/kjo.2025.0008","DOIUrl":"10.3341/kjo.2025.0008","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the anatomical and functional outcomes in cases of re-switching to previous anti?vascular endothelial growth factor (anti-VEGF) agents due to intraocular inflammation (IOI) following a switch to brolucizumab in neovascular age-related macular degeneration.</p><p><strong>Methods: </strong>This study included patients with neovascular age-related macular degeneration who switched to brolucizumab and discontinued brolucizumab treatment due to IOI, with a follow-up duration of at least 6 months before and after brolucizumab treatment period. Changes in best-corrected visual acuity, central macular thickness, central choroidal thickness, and retinal fluid on optical coherence tomography were evaluated.</p><p><strong>Results: </strong>A total of 16 eyes from 16 patients were reviewed. Two patients (12.5%) achieved complete fluid resolution before brolucizumab treatment, which increased to 15 (93.8%) during brolucizumab therapy. However, after switching back to other anti-VEGF agents, the proportion of patients with dry macula decreased to 37.5%. There were no statistically significant changes in best-corrected visual acuity, central macular thickness, central choroidal thickness throughout the study period.</p><p><strong>Conclusions: </strong>In cases where brolucizumab treatment was discontinued due to IOI and switched back to other anti-VEGF agents, the anatomical response was insufficient, indicating the need for alternative treatment options.</p>","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"493-500"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145071517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Economic Evaluation of Diabetic Retinopathy Screening in Developing Countries: A Systematic Review. 发展中国家糖尿病视网膜病变筛查的经济评价:系统综述。
Pub Date : 2025-12-01 Epub Date: 2025-09-19 DOI: 10.3341/kjo.2025.0047
Ari Andayani, Kevin Anggakusuma Hendrawan, Yudistira, Ni Made Ari Suryathi, Titiek Ernawati

Purpose: The purpose of this study was to evaluate economic aspect of diabetic retinopathy (DR) screening strategies in developing countries. It focused on the cost-effectiveness of artificial intelligence (AI) and telemedicine compared to standard care.

Methods: A structured literature search was conducted using PubMed, ScienceDirect, the Cochrane Library, and Google Scholar. Studies were included if they involved patients with type 1 or type 2 diabetes mellitus, conducted in low- or middle-income countries at the time of the study, compared AI or telemedicine-based intervention with standard care, and performed a health economic assessment or provided sufficient data to assess cost-effectiveness.

Results: Seven studies were identified from China, Thailand, Brazil, and India. Of these, four applied cost-utility analysis, two used cost-effectiveness analysis, and one employed both approaches. Three studies evaluated AI-based screening, three focused on telemedicine, and one examined a combined AI-assisted telemedicine model. All studies compared these interventions to standard care, with some using no screening as the comparator. Across all studies, AI and telemedicine-based screening strategies were found to be cost-effective, though the degree of economic benefit varied depending on the model, setting, and assumptions used.

Conclusions: This review supports the cost-effectiveness and feasibility of AI- and telemedicine-based DR screening in developing countries. While most strategies proved economically viable, cost savings and health gains varied. Screening frequency and patient compliance were key factors influencing successful implementation.

目的:本研究的目的是评估发展中国家糖尿病视网膜病变(DR)筛查策略的经济方面。它侧重于与标准护理相比,人工智能(AI)和远程医疗的成本效益。方法:使用PubMed、ScienceDirect、Cochrane Library和谷歌Scholar进行结构化文献检索。纳入研究时在低收入或中等收入国家进行的涉及1型或2型糖尿病患者的研究,将人工智能或基于远程医疗的干预与标准护理进行比较,并进行健康经济评估或提供足够的数据以评估成本效益。结果:从中国、泰国、巴西和印度确定了7项研究。其中,四个应用了成本效用分析,两个使用了成本效益分析,一个采用了两种方法。三项研究评估了基于人工智能的筛查,三项研究侧重于远程医疗,一项研究考察了人工智能辅助的联合远程医疗模型。所有的研究都将这些干预措施与标准治疗进行了比较,有些研究没有使用筛查作为比较。在所有研究中,发现人工智能和基于远程医疗的筛查策略具有成本效益,尽管经济效益的程度取决于所使用的模型、环境和假设。结论:本综述支持发展中国家基于人工智能和远程医疗的DR筛查的成本效益和可行性。虽然大多数战略在经济上是可行的,但成本节约和健康收益各不相同。筛查频率和患者依从性是影响成功实施的关键因素。
{"title":"Economic Evaluation of Diabetic Retinopathy Screening in Developing Countries: A Systematic Review.","authors":"Ari Andayani, Kevin Anggakusuma Hendrawan, Yudistira, Ni Made Ari Suryathi, Titiek Ernawati","doi":"10.3341/kjo.2025.0047","DOIUrl":"10.3341/kjo.2025.0047","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to evaluate economic aspect of diabetic retinopathy (DR) screening strategies in developing countries. It focused on the cost-effectiveness of artificial intelligence (AI) and telemedicine compared to standard care.</p><p><strong>Methods: </strong>A structured literature search was conducted using PubMed, ScienceDirect, the Cochrane Library, and Google Scholar. Studies were included if they involved patients with type 1 or type 2 diabetes mellitus, conducted in low- or middle-income countries at the time of the study, compared AI or telemedicine-based intervention with standard care, and performed a health economic assessment or provided sufficient data to assess cost-effectiveness.</p><p><strong>Results: </strong>Seven studies were identified from China, Thailand, Brazil, and India. Of these, four applied cost-utility analysis, two used cost-effectiveness analysis, and one employed both approaches. Three studies evaluated AI-based screening, three focused on telemedicine, and one examined a combined AI-assisted telemedicine model. All studies compared these interventions to standard care, with some using no screening as the comparator. Across all studies, AI and telemedicine-based screening strategies were found to be cost-effective, though the degree of economic benefit varied depending on the model, setting, and assumptions used.</p><p><strong>Conclusions: </strong>This review supports the cost-effectiveness and feasibility of AI- and telemedicine-based DR screening in developing countries. While most strategies proved economically viable, cost savings and health gains varied. Screening frequency and patient compliance were key factors influencing successful implementation.</p>","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"566-579"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12718733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Korean journal of ophthalmology : KJO
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1